Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 2/20 | 0.64 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.64 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.64 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.64 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9407912 | 0.98 | S1PR2 (0.67) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL14823591 | 0.96 | S1PR2 (0.60) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL8820729 | 0.96 | S1PR2 (0.65) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL31570922 | 0.96 | S1PR2 (0.65) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL10716895 | 0.93 | S1PR2 (0.56) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL5362759 | 0.90 | S1PR2 (0.63) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL21984539 | 0.88 | S1PR2 (0.61) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL8818981 | 0.86 | S1PR2 (0.65) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL3118704 | 0.86 | S1PR2 (0.65) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL8818989 | 0.86 | S1PR2 (0.65) | S1PR2S1PR4S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5360804-A | STABILITY | L'OREAL (FR) | 1994-11-01 | — | — | US | claimed |
| US-20240150350-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024092069-A1 | CXCR4 INHIBITORS FOR TREATMENT OF NEUROLOGICAL DISEASES | X4 PHARMACEUTICALS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-116554168-A | CXCR4 inhibitors and uses thereof | X4 制药有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-3990456-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 Pharmaceuticals, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-11306088-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| WO-2021263203-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20210363139-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-11-25 | — | — | US | disclosed |
| US-10988465-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1809613-A2 | METHODS OF MAKING 2,6-DIARYL PIPERIDINE DERIVATIVES | ANORMED INC. (CA) | 2007-07-25 | — | — | EP | disclosed |
| EP-1809613-A2 | METHODS OF MAKING 2,6-DIARYL PIPERIDINE DERIVATIVES | ANORMED INC. (CA) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006049764-A3 | METHODS OF MAKING 2,6-DIARYL PIPERIDINE DERIVATIVES | ANORMED INC (CA) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006049764-A2 | METHODS OF MAKING 2,6-DIARYL PIPERIDINE DERIVATIVES | ANORMED INC. (CA) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006049764-A2 | METHODS OF MAKING 2,6-DIARYL PIPERIDINE DERIVATIVES | ANORMED INC. (CA) | 2006-05-11 | — | — | WO | disclosed |
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ANORMED CORPORATION (CA) | 2005-07-14 | — | — | US | disclosed |
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ANORMED CORPORATION (CA) | 2005-07-14 | — | — | US | disclosed |
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ANORMED CORPORATION (CA) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ALDH7A1, DPYD, ALDH1A1 | S1PR2 383/4885S1PR4 637/4885S1PR1 587/4885 |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | S1PR2 293/4885S1PR4 261/4885S1PR1 245/4885 |
| US-20210363139-A1 | CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCL12, CXCR3 | S1PR2 293/4885S1PR4 261/4885S1PR1 245/4885 |
| US-10988465-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | S1PR2 293/4885S1PR4 261/4885S1PR1 245/4885 |
| US-20240150350-A1 | CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCL12, CXCR3 | S1PR2 293/4885S1PR4 261/4885S1PR1 245/4885 |
| US-11306088-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | S1PR2 293/4885S1PR4 261/4885S1PR1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.